318160 — Cell Bio Human Tech Co Income Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsSpeculativeMicro CapSuper Stock

Annual income statement for Cell Bio Human Tech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	28,588	35,161	27,545	27,324	28,419
Cost of Revenue
Gross Profit	9,949	10,225	7,643	7,729	9,045
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	23,313	29,837	24,442	24,548	24,382
Operating Profit	5,276	5,324	3,103	2,777	4,037
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,789	4,479	3,541	-812	5,191
Provision for Income Taxes
Net Income After Taxes	4,215	3,113	2,890	-1,857	4,379
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,187	3,131	2,890	-1,857	4,379
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,776	2,824	2,890	-1,857	4,379
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	488	399	421	-174	490
Dividends per Share